Eis Eczacibasi Ilac, Sinai Ve Finansal Yatirimlar Sanayi Ve Ticaret A.s. · BIST:ECILC
Eis Eczacibasi Ilac, Sinai Ve Finansal Yatirimlar Sanayi Ve Ticaret A.s — EİS Eczacıbaşı İlaç, Sınai ve Finansal Yatırımlar Sanayi ve Ticaret A.Ş. — Shareholder Meeting (April 2023)
22 slides from Eis Eczacibasi Ilac, Sinai Ve Finansal Yatirimlar Sanayi Ve Ticaret A.s's shareholder meeting presentation, Apr 11, 2023
Slide 1: Ordinary General Assembly Meeting, April 11, 2023
EİS ECZACIBAŞI İLAÇ, SINAİ VE FİNANSAL YATIRIMLAR SANAYİ ve TİCARET A.Ş. ORDINARY GENERAL ASSEMBLY MEETING April 11, 2023
Slide 2: A healthy future for your investments
A healthy future for your investments 1/21
Slide 3: Content
Content ▪ General Information ▪ Activity Information ▪ Consolidated Indicators ▪ Activities in the Health Sector ▪ Activities in Real Estate Development ▪ Future Strategies ▪ 2022 Summary Data of Subsidiaries, Joint Ventures and Affiliates 2/21
Slide 4: General Information
General Information ▪ General Information ▪ Shareholding Structure ▪ Affiliates and Partnerships ▪ Consolidated Structure 3/21
Slide 5: Shareholding Structure of EİS
Shareholding Structure of EİS Paid-up Capital: TL 685,260,000 Amount (Thousand Shareholder Share (%) TL) ECZACIBAŞI HOLDİNG A.Ş. 346,845 50.62 ECZACIBAŞI YATIRIM HOLDİNG ORT. A.Ş. 209,804 30.62 OTHER 128,611 18.76 TOTAL 685,260 100.00 Eczacıbaşı Holding A.Ş. 18.76% Eczacıbaşı Yatırım Holding Ortaklı
Slide 6: EİS - Affiliates and Partnerships
EİS - Affiliates and Partnerships Nominal Shareholding Capital (Thousand Subsidiaries Shareholding Ratio (%) Amount (Thousand TL) TL) EİP Eczacıbaşı İlaç Pazarlama A.Ş. 99.92 56,055 56,100 Gensenta İlaç Sanayi ve Ticaret A.Ş. 99.96 576,955 577,196 Eczacıbaşı Gayrimenkul Geliştirme ve Yatırım A.Ş. 99
Slide 7: EİS Consolidated Structure
EİS Consolidated Structure EİS Health Other Gensenta İlaç San. 99.9% Eczacıbaşı Holding 37.3% Real Estate Development Ecz. İlaç Pazarlama 99.9% Ekom Ecz. Dış Tic. 26.4% Ecz. Gayrimenkul A.Ş. 99.5% Ecz. İlaç Ticaret VitrA Karo 25.0% 99.9% Eczacıbaşı-Monrol 65.0% Ecz. Bilişim 11.2% Subsidiaries Joint
Slide 8: Activity Information
Activity Information ▪ Activity Information ▪ Consolidated Indicators ▪ Activities in the Health Sector ▪ Activities in Real Estate Development 7/21
Slide 9: EİS - Consolidated Indicators (TL Million)
EİS - Consolidated Indicators (TL Million) Total Assets Total Assets Total Equity ▪ TL 3 Billion increase by bringing investment properties to fair value +130% +108% ▪ TL 1.8 Billion increase in total assets with 23,232 18,754 the consolidation of Gensenta, ▪ In 2022, the effect of fair value increa
Slide 10: EİS - Consolidated Indicators (TL Million)
EİS - Consolidated Indicators (TL Million) Revenue ▪ EİP Eczacıbaşı İlaç Pazarlama's revenue increased by (+45%) compared to the Revenue Distribution Revenue previous year with the contribution of increased volume in terms of boxes (+9.2%) as well as the increases in +66% medication prices in Februa
Slide 11: 2022 Key Developments & Contributions
2022 Key Developments & Contributions ▪ In line with the goal of expanding Eczacıbaşı-Monrol's products and services in foreign markets, we established a new company in Germany, "Monrol GmbH", for the development and production of radiopharmaceutical products. ▪ We acquired Gensenta, one of Turkey's
Slide 12: Gains due to Gansente Acquisition
Gains due to Gansente Acquisition ▪ Adding pharmaceuticals and biosimilars, pharmaceutical raw material production and export competencies in healthcare to the portfolio, ▪ Access to foreign markets; exports to more than 30 countries, 43% share of foreign revenues in total revenues, ▪ Strategic busi
Slide 13: Activities in the Health Sector - 2022
Activities in the Health Sector - 2022 Gensenta ▪ TL 1.4 billion in turnover ▪ USD 8 million Vial 2 GMP upgrade investment to increase capacity by an additional 10 million vials by the end of 2023, ▪ GMP certificate renewal approvals. 12/21
Slide 14: Activities in the Health Sector - 2022
Activities in the Health Sector - 2022 Eczacıbaşı İlaç Pazarlama ▪ Digital transformation projects, ▪ 12 new product development/license agreements, ▪ The share of our own products in total turnover is 12%. 13/21
Slide 15: Activities in the Health Sector - 2022
Activities in the Health Sector - 2022 Eczacıbaşı - Monrol ▪ Marketing authorization applications for Lu-177 in Germany, Austria, the Netherlands and Belgium, ▪ International collaborations, ▪ Exports to more than 60 countries, ▪ Construction of a new production area in Gebze in compliance with FDA'
Slide 16: Global market growth supported by Theranostics and CDMO
Global market growth supported by Theranostics* and CDMO** Global pharma companies' investment in theranostics exceeds €10 Billion US and EU account for more than 75% of the market $ Billion Global Nuclear Medicine Market 35 ‘21-31 BYBO CDMO (Million Euros) 30 19% 25 1,000 Radiopharmacy 2024 20 New
Slide 17: Turkish Pharmaceutical Market & Market Share - 2022
Turkish Pharmaceutical Market & Market Share - 2022 Turkish Pharmaceutical Market Hospital Pharmacy Compound Annual Growth Million TL Rate 2018-2022 121,135 39% 12,675 Total Value 39% Volume: 6% 32,851 108,460 Price: 33% 3,596 29,254 2018 2022 Market Share ▪ With the Gensenta acquisition, our market
Slide 18: Health Trends in Turkey
Health Trends in Turkey Financial Policy Objectives Improving the Price increase for pharmaceutical medicines under TL 55 ecosystem Increasing SUT prices by Export subsidies 55% Earlier exchange rate Supporting production hikes and R&D 18/21
Slide 19: Future Strategies
Future Strategies ▪ HEALTH: Implementing investment strategies/actions focused on markets and therapeutic areas where growth is expected, in line with production, export, innovation and cost-effectiveness priorities ▪ EİP: Achieving sustainable growth locally and in Europe with an expanded export po
Slide 20: ECILC-BIST 100 2022 Performance
ECILC-BIST 100 2022 Performance 20/21
Slide 21: EİS - 2022 Financial Data of Subsidiaries, Joint Ventures and Affiliates
EİS - 2022 Financial Data of Subsidiaries, Joint Ventures and Affiliates Esas Faaliyet Net Dönem Ortaklık Varlıklar Özkaynaklar Hasılat Karı / Zararı Karı / Zararı Oranı (%) (Bin TL) (Bin TL) (Bin TL) 31 Aralık 2022 itibarıyla(*) (Bin TL) (Bin TL) Bağlı Ortaklıklar Gensenta İlaç Sanayi ve Ticaret A.
Slide 22: Thank You
cs Thank You